SummaryBackgroundChronic Chagas disease has indeterminate and cardiac forms associated with distinct immune profiles. Infection with SARS-CoV-2, compared with other causes of hospital admission, represented the highest risk factor for in-hospital mortality among patients with Chagas disease during the COVID-19 pandemic. Nevertheless, whether SARS-CoV-2 infection disrupts pre-existing Trypanosoma cruzi-specific immunity and affects cardiac progression remains unclear.MethodsWe investigated adults with chronic Chagas disease followed during the COVID-19 pandemic and stratified by Chagas disease clinical form and COVID-19 status. Clinical progression was assessed during 1-yr follow-up. Peripheral blood mononuclear cells were stimulated with T. cruzi lysate, and antigen-induced CD4 and CD8 T-cell responses were quantified by flow cytometry and expressed as log2 stimulation indices. Serum cytokines, chemokines, growth factors, and cardiovascular risk-associated proteins were measured by multiplex assays. Hierarchical clustering and Spearman correlation networks were used to assess coordinated immune changes.FindingsAmong 172 patients, 37 had mild COVID-19 and 135 had no history of COVID-19. Cardiac progression was more frequent in patients with mild COVID-19 than in those without COVID-19 (16·2% vs 5·2%; adjusted OR 3·64, 95% CI 1·06–12·33; p=0·035). Indeterminate patients without COVID-19 showed IL-10/IL-17/LAP-skewed T. cruzi-specific responses, whereas this profile was reduced in indeterminate patients with COVID-19, in favor of higher IL-1β and enhanced CD8 response. Cardiac patients with COVID-19 retained a Th1-skewed profile, with higher TNF, IL-6, CD4+IFN-γ+ responses, and denser serum networks linking inflammatory cytokines, chemokines, and cardiovascular risk-associated proteins, with a loss of correlations between regulatory and inflammatory T cell populations.InterpretationMild SARS-CoV-2 infection was associated with cardiac progression and immune-network remodeling in chronic Chagas disease, marked by loss of regulatory and Th17 features in indeterminate disease and amplification of inflammatory coordination in cardiomyopathy.FundingFiocruz, FAPERJ, CNPq, CAPES and GIISER (Gates Foundation).